April 19, 2024
A lady places in eye drops. Picture through @lenz_tx X

Lenz Therapeutics stated on Wednesday its lead experimental drug being examined in sufferers with a typical age-related eye dysfunction confirmed enchancment in nearsightedness in a late-stage research.

Shares of the Del Mar-based firm, which gained as a lot as 17% earlier within the day, have been final buying and selling 4.2% larger at $21.89.

The once-daily eye drop, LNZ100, is being examined to deal with presbyopia, which causes incapacity to concentrate on close to objects and impacts an estimated 128 million individuals in america, in keeping with the corporate.

Its therapy choices embrace carrying studying glasses, contact lenses and refractive surgical procedure. Abbvie’s Vuity bagged the U.S. FDA approval in 2021 as the primary eye drop for presbyopia. Firms reminiscent of Eyenovia and Ocuphire Pharma are additionally growing remedies for the illness.

The late-stage research testing Lenz’s eye drop comprised two six-week efficacy trials and a six-month security trial. The trials enrolled a complete of 1,059 individuals starting from ages 45 to 75 years.

The therapy helped enhance close to imaginative and prescient with out impacting distant imaginative and prescient for 71% of the sufferers at three hours post-treatment.

Primarily based on the trial, the firm plans to submit a U.S. advertising and marketing utility for LNZ100 in mid-2024.

Lenz stated its one other drug, LNZ101, additionally confirmed comparable outcomes however didn’t present superiority to LNZ100.

Rival Eyenovia is testing its drug supply gadget Optejet in late-stage trials with its experimental drug to deal with presbyopia. Ocuphire can also be testing its eye drop in a late-stage trial.